Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor.
作者信息
Biondi Andrea, Cario Gunnar, De Lorenzo Paola, Castor Anders, Conter Valentino, Leoni Veronica, Gandemer Virginie, Pieters Rob, Stary Jan, Escherich Gabriele, Campbell Myriam, Attarbaschi Andishe, Li Chi-Kong, Vora Ajay, Bradtke Jutta, Saha Vaskar, Valsecchi Maria Grazia, Schrappe Martin
机构信息
Pediatric Department, University of Milano-Bicocca, Fondazione MBBM/San Gerardo Hospital, Monza, Italy
Centro Ricerca Tettamanti, Pediatric Department, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy.
出版信息
Haematologica. 2019 Jan;104(1):e13-e16. doi: 10.3324/haematol.2018.199422. Epub 2018 Sep 13.
Abstract
摘要
相似文献
1
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor.EsPhALL2004研究治疗儿童费城染色体阳性急性淋巴细胞白血病的长期随访：诊断时高白细胞计数是最强的预后因素。
Haematologica. 2019 Jan;104(1):e13-e16. doi: 10.3324/haematol.2018.199422. Epub 2018 Sep 13.
2
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.异基因造血干细胞移植，尤其是单倍体相合移植，可能改善酪氨酸激酶抑制剂时代费城染色体阳性急性淋巴细胞白血病高危儿科患者的长期生存。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1611-1620. doi: 10.1016/j.bbmt.2018.12.007. Epub 2018 Dec 8.
3
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.异基因造血干细胞移植与酪氨酸激酶抑制剂联合化疗治疗费城染色体阳性急性淋巴细胞白血病。
Biol Blood Marrow Transplant. 2018 Apr;24(4):741-750. doi: 10.1016/j.bbmt.2017.12.777. Epub 2017 Dec 13.
4
Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia.费城染色体阳性 B 细胞急性淋巴细胞白血病患儿同时使用伊马替尼和大剂量甲氨蝶呤会导致急性肾损伤和甲氨蝶呤清除延迟。
J Pediatr Hematol Oncol. 2021 Mar 1;43(2):e296-e300. doi: 10.1097/MPH.0000000000001816.
5
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.酪氨酸激酶抑制剂对儿童费城染色体阳性急性淋巴细胞白血病微小残留病和预后的影响。
Cancer. 2014 May 15;120(10):1514-9. doi: 10.1002/cncr.28598. Epub 2014 Feb 5.
6
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.达沙替尼与伊马替尼治疗费城染色体阳性儿童急性淋巴细胞白血病的效果比较：一项随机临床试验。
JAMA Oncol. 2020 Mar 1;6(3):358-366. doi: 10.1001/jamaoncol.2019.5868.
7
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.伊马替尼诱导治疗后用于费城染色体阳性儿童和青少年急性淋巴细胞白血病（EsPhALL）的治疗：一项随机、开放标签、分组研究。
Lancet Oncol. 2012 Sep;13(9):936-45. doi: 10.1016/S1470-2045(12)70377-7. Epub 2012 Aug 14.
8
Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.伊马替尼时代单倍体相合造血干细胞移植治疗儿童费城染色体阳性急性淋巴细胞白血病
Leuk Res. 2017 Aug;59:136-141. doi: 10.1016/j.leukres.2017.05.021. Epub 2017 Jun 1.
9
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.伊马替尼改善费城染色体阳性急性淋巴细胞白血病患者的早期无事件生存率：一项儿童肿瘤学组研究
J Clin Oncol. 2009 Nov 1;27(31):5175-81. doi: 10.1200/JCO.2008.21.2514. Epub 2009 Oct 5.
10
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.伊马替尼治疗儿童费城染色体阳性急性淋巴细胞白血病（EsPhALL2010）：一项前瞻性、多组、开放标签、单臂临床试验。
Lancet Haematol. 2018 Dec;5(12):e641-e652. doi: 10.1016/S2352-3026(18)30173-X.
引用本文的文献
1
No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study.儿童费城染色体阳性急性淋巴细胞白血病预防性颅脑放疗无明确获益：EsPhALL2010研究的回顾性分析
Haematologica. 2024 Nov 1;109(11):3766-3770. doi: 10.3324/haematol.2024.285253.
2
Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia.高危儿童急性淋巴细胞白血病的生物标志物
Cancers (Basel). 2024 Feb 21;16(5):858. doi: 10.3390/cancers16050858.
3
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.初诊 BCR::ABL1 阳性 BCP-ALL 中酪氨酸激酶抑制剂耐药与激酶结构域突变之外的因素相关。
Blood Adv. 2024 Apr 23;8(8):1835-1845. doi: 10.1182/bloodadvances.2023012162.
4
The Outcome of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Experience from a Referral Center in South India.小儿费城染色体阳性急性淋巴细胞白血病的治疗结果：来自印度南部一家转诊中心的经验。
Indian J Hematol Blood Transfus. 2024 Jan;40(1):61-67. doi: 10.1007/s12288-023-01684-9. Epub 2023 Aug 9.
5
Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.在中国，伊马替尼与达沙替尼联合常规化疗治疗费城染色体阳性儿童急性淋巴细胞白血病的成本效果分析。
BMC Health Serv Res. 2023 Jun 19;23(1):652. doi: 10.1186/s12913-023-09600-7.
6
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.BCR::ABL1 阳性急性淋巴细胞白血病中的微小残留病：在典型急性淋巴细胞白血病和慢性粒细胞白血病样疾病中的不同意义。
Leukemia. 2022 Dec;36(12):2793-2801. doi: 10.1038/s41375-022-01668-0. Epub 2022 Aug 6.
7
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia.小儿急性淋巴细胞白血病中枢神经系统疾病的管理
Curr Hematol Malig Rep. 2022 Feb;17(1):1-14. doi: 10.1007/s11899-021-00640-6. Epub 2022 Jan 13.
8
The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why?酪氨酸激酶抑制剂在儿科血液肿瘤学中的应用——何时及为何使用？
Int J Mol Sci. 2021 Nov 8;22(21):12089. doi: 10.3390/ijms222112089.
9
Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis.酪氨酸激酶抑制剂用于儿童费城染色体阳性急性淋巴细胞白血病：一项系统评价和荟萃分析。
BMJ Open. 2021 Jan 19;11(1):e042814. doi: 10.1136/bmjopen-2020-042814.
10
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.酪氨酸激酶抑制剂时代前伴有 ABL 类融合的小儿急性淋巴细胞白血病患者的结局：一项多中心、回顾性、队列研究。
Lancet Haematol. 2021 Jan;8(1):e55-e66. doi: 10.1016/S2352-3026(20)30353-7. Epub 2020 Dec 22.
本文引用的文献
1
Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.达沙替尼联合强化化疗治疗费城染色体阳性儿童、青少年和年轻成人急性淋巴细胞白血病：儿童肿瘤学组 AALL0622 试验结果。
J Clin Oncol. 2018 Aug 1;36(22):2306-2314. doi: 10.1200/JCO.2017.76.7228. Epub 2018 May 29.
2
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.基于免疫球蛋白/T 细胞受体和 BCR/ABL1 方法学，伊马替尼治疗后基于微小残留病灶预测费城染色体阳性急性淋巴细胞白血病的欧洲研究组的诱导治疗后治疗的费城染色体阳性急性淋巴细胞白血病的预测价值。
Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.
3
Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.儿童及青少年费城染色体阳性急性淋巴细胞白血病的治疗进展
Br J Haematol. 2016 Mar;172(6):855-69. doi: 10.1111/bjh.13896. Epub 2016 Jan 15.
4
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.伊马替尼治疗儿童费城染色体阳性急性淋巴细胞白血病的长期随访：儿童肿瘤学组AALL0031研究
Leukemia. 2014 Jul;28(7):1467-71. doi: 10.1038/leu.2014.30. Epub 2014 Jan 20.
5
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.伊马替尼诱导治疗后用于费城染色体阳性儿童和青少年急性淋巴细胞白血病（EsPhALL）的治疗：一项随机、开放标签、分组研究。
Lancet Oncol. 2012 Sep;13(9):936-45. doi: 10.1016/S1470-2045(12)70377-7. Epub 2012 Aug 14.
6
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.1995 年至 2005 年间诊断为费城染色体阳性急性淋巴细胞白血病的儿童的临床结果。
J Clin Oncol. 2010 Nov 1;28(31):4755-61. doi: 10.1200/JCO.2010.30.1325. Epub 2010 Sep 27.
7
'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'.儿童急性淋巴细胞白血病大型前瞻性临床试验的长期结果教育研讨会（1985 - 2000年）
Leukemia. 2010 Feb;24(2):253-4. doi: 10.1038/leu.2009.276.
8
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.伊马替尼改善费城染色体阳性急性淋巴细胞白血病患者的早期无事件生存率：一项儿童肿瘤学组研究
J Clin Oncol. 2009 Nov 1;27(31):5175-81. doi: 10.1200/JCO.2008.21.2514. Epub 2009 Oct 5.
9
Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).异基因造血细胞移植（异基因HCT）用于治疗小儿费城染色体阳性急性淋巴细胞白血病（ALL）。
Pediatr Blood Cancer. 2009 Dec 15;53(7):1289-94. doi: 10.1002/pbc.22263.
10
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).基于风险和反应的儿童B前体急性淋巴细胞白血病分类：来自儿童肿瘤学组（POG）和儿童癌症组（CCG）预后标志物的联合分析
Blood. 2007 Feb 1;109(3):926-35. doi: 10.1182/blood-2006-01-024729. Epub 2006 Sep 26.
Zotero 插件